Marivic Quintinita
Family · Titusville, FLNPI 1730381641
Payments from drug & device makers
Across 313 payments — averaging $47.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Johnson & Johnson$493
- Takeda Pharmaceuticals U.S.A., Inc.$460
- Bristol Myers Squibb$322
- Evoke Pharma, Inc.$294
- Pfizer$269
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$8,60058%
- Travel & lodging$450%
- Food & beverage$6,10641%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 157 | $11,105 |
| Johnson & Johnson | 16 | $493 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $460 |
| Bristol Myers Squibb | 15 | $322 |
| Evoke Pharma, Inc. | 13 | $294 |
| Pfizer | 11 | $269 |
| Phathom Pharmaceuticals, Inc. | 11 | $229 |
| AstraZeneca | 2 | $222 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $211 |
| Madrigal Pharmaceuticals | 9 | $196 |
| Merck | 8 | $144 |
| Braintree Laboratories, Inc. | 7 | $142 |
| Ardelyx, Inc. | 5 | $102 |
| Intercept Pharmaceuticals, Inc. | 4 | $83 |
| Cvrx, Inc. | 1 | $79 |
| Gilead | 4 | $79 |
| Sanofi | 3 | $65 |
| Boehringer Ingelheim | 2 | $57 |
| Nestle Healthcare Nutrition Inc. | 3 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Celltrion USA Inc. | 1 | $23 |
| Vivus LLC | 2 | $22 |
| Enterra Medical, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,762 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 19 | $105,090 |
| LinzessLinaclotide | 53 | $44,631 |
| VoqueznaVonoprazan Fumarate | 20 | $21,084 |
| Mesalamine | 38 | $8,565 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 57 | $6,857 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 88 | $5,856 |
| Dicyclomine Hcl | 114 | $4,057 |
| Mesalamine ErMesalamine | 26 | $3,511 |
| Omeprazole | 176 | $3,332 |
| CholestyramineCholestyramine (With Sugar) | 30 | $2,823 |
| Pantoprazole Sodium | 158 | $1,832 |
| Esomeprazole Magnesium | 38 | $1,553 |
| Sucralfate | 42 | $1,442 |
| Lansoprazole | 14 | $991 |
| Budesonide EcBudesonide | 11 | $962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $11,105 | $149,72172 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $229 | $21,08420 claims |
| Braintree Laboratories, Inc.Suflave | $142 | $6,85757 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Titusville
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.